LPCN
Lipocine Inc

14,447
Mkt Cap
$17.56M
Volume
13,306.00
52W High
$5.50
52W Low
$2.52
PE Ratio
-3.20
LPCN Fundamentals
Price
$3.25
Prev Close
$3.16
Open
$3.16
50D MA
$2.92
Beta
0.69
Avg. Volume
57,667.52
EPS (Annual)
-$0.0016
P/B
1.25
Rev/Employee
$699,884.00
Loading...
Loading...
News
all
press releases
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Lipocine (LPCN) delivered earnings and revenue surprises of -5.36% and +15.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 PR Newswire SALT LAKE CITY...
PR Newswire·19d ago
News Placeholder
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek PR Newswire SALT LAKE CITY, Nov. 4, 2025 SALT LAKE CITY, Nov. 4, 2025 /PRNewswire...
PR Newswire·21d ago
News Placeholder
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 Lipocine Receives Updated Regulatory Guidance on LPCN 1154 PR Newswire SALT LAKE CITY, Feb. 6, 2025 SALT LAKE CITY, Feb. 6, 2025...
PR Newswire·10mo ago
News Placeholder
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a...
PR Newswire·11mo ago
News Placeholder
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver...
PR Newswire·1y ago
News Placeholder
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 PR Newswire SALT LAKE CITY...
PR Newswire·1y ago
News Placeholder
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize...
PR Newswire·1y ago
News Placeholder
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results PR Newswire SALT LAKE CITY, Oct. 10, 2024 Quantitative...
PR Newswire·1y ago

Latest LPCN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.